Volume 23, Issue 3 (7-2024)
JRUMS 2024, 23(3): 264-272 |
Back to browse issues page
Ethics code: IR. ZBMU. REC.1400.074
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Dabirzadeh M, Hossein Beigi R, Poursamimi J, Arab Yaghoobi L. Investigation of the Serum Levels of TGF-β and IL-6 Cytokines Effective on the Immune System of Diabetic Patients with Toxoplasma Parasitic Infection: A Short Report. JRUMS 2024; 23 (3) :264-272
URL: http://journal.rums.ac.ir/article-1-7263-en.html
URL: http://journal.rums.ac.ir/article-1-7263-en.html
Abstract: (337 Views)
Background and Objectives: Cytokines play an essential role in regulating the interaction of immune cells in diabetes and infections such as toxoplasmosis. This study was conducted to investigate the serum levels of Interleukin-6 (IL-6) and Transforming Growth Factor-Beta (TGF-β) in diabetic patients with toxoplasmosis.
Materials and Methods: This study was conducted in Zabol City on patients with type I and type II diabetes, both with and without toxoplasmosis. The serum levels of target cytokines were measured using the ELISA method. Data analysis was performed using one-way ANOVA, and chi-square test was utilized to examine demographic indices.
Results: A significant increase in TGF-β levels was observed in the group with type II diabetes and toxoplasmosis. Additionally, a slight rise in serum IL-6 levels was noted in the group with type I diabetes. However, the level of TGF-β was decreased in this group.
Conclusions: The present study revealed that an increase in TGF-β and a decrease in IL-6 in patients with type II diabetes and toxoplasmosis may indicate a reduction in inflammation within this specific group.
Keywords: Cytokines, Diabetes, Toxoplasmosis, Inflammation, Immune
Funding: This study was funded by Zabol University of Medical Sciences.
Conflict of interest: None declared.
Ethical considerations: The Ethics Committee of Zabol University of Medical Sciences approved the study (IR.ZBMU.REC.1400.074).
Authors’ contributions:
- Conceptualization: Javad Poursamimi, Mansour Debirzadeh
- Methodology: Javad Poursamimi, Mansour Debirzadeh
- Data collection: Javad Poursamimi, Mansour Debirzadeh, Roghayeh Hossein Beigi
- Formal analysis: Javad Poursamimi
- Supervision: Javad Poursamimi
- Project administration: Javad Poursamimi
- Writing - original draft: Javad Poursamimi, Mansour Debirzadeh
- Writing - review & editing: Ladan Arab Yaqoubi
Materials and Methods: This study was conducted in Zabol City on patients with type I and type II diabetes, both with and without toxoplasmosis. The serum levels of target cytokines were measured using the ELISA method. Data analysis was performed using one-way ANOVA, and chi-square test was utilized to examine demographic indices.
Results: A significant increase in TGF-β levels was observed in the group with type II diabetes and toxoplasmosis. Additionally, a slight rise in serum IL-6 levels was noted in the group with type I diabetes. However, the level of TGF-β was decreased in this group.
Conclusions: The present study revealed that an increase in TGF-β and a decrease in IL-6 in patients with type II diabetes and toxoplasmosis may indicate a reduction in inflammation within this specific group.
Keywords: Cytokines, Diabetes, Toxoplasmosis, Inflammation, Immune
Funding: This study was funded by Zabol University of Medical Sciences.
Conflict of interest: None declared.
Ethical considerations: The Ethics Committee of Zabol University of Medical Sciences approved the study (IR.ZBMU.REC.1400.074).
Authors’ contributions:
- Conceptualization: Javad Poursamimi, Mansour Debirzadeh
- Methodology: Javad Poursamimi, Mansour Debirzadeh
- Data collection: Javad Poursamimi, Mansour Debirzadeh, Roghayeh Hossein Beigi
- Formal analysis: Javad Poursamimi
- Supervision: Javad Poursamimi
- Project administration: Javad Poursamimi
- Writing - original draft: Javad Poursamimi, Mansour Debirzadeh
- Writing - review & editing: Ladan Arab Yaqoubi
Type of Study: Research |
Subject:
ايمونولوژي
Received: 2024/01/7 | Accepted: 2024/07/3 | Published: 2024/07/20
Received: 2024/01/7 | Accepted: 2024/07/3 | Published: 2024/07/20
References
1. Tosur M, Geyer SM, Rodriguez H, Libman I, Baidal DA, Redondo MJ. Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk. Diabetologia 2018; 61(9): 2043-53.
2. Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2020; 13: 3611-16.
3. Mensah-Brown EPK, Shahin A, Al-Shamisi M, Wei X, Lukic ML. IL-23 leads to diabetes induction after subdiabetogenic treatment with multiple low doses of streptozotocin. Eur J Immunol 2006; 36(1): 216–23.
4. Oliveira-Scussel AC de M, Ferreira PTM, Resende R de S, Ratkevicius-Andrade CM, Gomes A de O, Paschoini MC, et al. Association of gestational diabetes mellitus and negative modulation of the specific humoral and cellular immune response against Toxoplasma gondii. Front Immunol 2022; 13(10.3389): 1–18.
5. Matowicka-Karna J, Dymicka-Piekarska V KH. Does Toxoplasma gondii infection affect the levels of IgE and cytokines (IL-5, IL-6, IL-10, IL-12, and TNF-alpha)? Clin Dev Immunol 2009; 2009, 1–4.
6. Thieme C, Schlickeiser S, Metzner S, Dames C PU. Immune mediator profile in aqueous humor differs in patients with primary acquired ocular toxoplasmosis and recurrent acute ocular toxoplasmosis. Mediators Inflamm 2019; 2019:1–12.
7. Beshay EV, El-Refai SA, Helwa MA, Atia AF DM. Toxoplasma gondii as a possible causative pathogen of type-1 diabetes mellitus: Evidence from case-control and experimental studies. Exp Parasitol 2018; 188: 93–101.
8. Dabirzadeh M, Sargazi M BS. Seroepidemiology of Toxoplasma gondii in diabetic patients type 2 by enzyme‑linked immunosorbent assay method in Zabol City, 2017–2018. J Res Med Sci 2024; 29(19): 1–7.
9. Nosaka K, Hunter M WW. The role of Toxoplasma gondii as a possible inflammatory agent in the pathogenesis of type 2 diabetes mellitus in humans. Fam Med Community Heal 2016; 4(4): 44–62.
10. Roohi A, Tabrizi M, Abbasi F, Ataie-Jafari A, Nikbin B, Larijani B, Qorbani M, Meysamie A, Asgarian-Omran H, Nikmanesh B BA. Serum IL-17, IL-23, and TGF-β levels in type 1 and type 2 diabetic patients and age-matched healthy controls. BioMed Research International 2014; Article ID 718946: 1-7.
11. Asgari Q, Motazedian MH, Khazanchin A, Mehrabani D NSS, Asgari Q, Motazedian MH, Khazanchin A, Mehrabani D, Naderi Shahabadi S. High Prevalence of Toxoplasma gondii Infection in Type i Diabetic Patients. J Parasitol Res 2021; 2021: 1–6.
12. Hilal AM HH. The role of some cytokines in diabetic patients infected with toxoplasmosis. Plant Arch 2019; 19(2): 602-5.
13. Kikodze N, Pantsulaia I, Kh R, Iobadze M, Dzhakhutashvili N, Pantsulaia N, Kukuladze N, Bikashvili N, Metreveli D CT. Cytokines and T regulatory cells in the pathogenesis of type 1 diabetes. Georgian Med News 2013; 222: 29–35.
14. Pradhan AD, Manson JE, Rifai N, Buring JE RP. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama 2001; 286(3): 327–34.
15. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and Diabetes. Diabetes 2005; 54(suppl_2): S114–24.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
